SCHEMBL5138425

SCHEMBL5138425

c1cc(-c2n[nH]cc2-c2ccc3c(c2)OCO3)nc(C2CC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCUN1D1 Q96GG9 2/20 0.40
TGFBR1 P36897 3/20 0.39
MAPK14 Q16539 2/20 0.39
RIPK2 O43353 1/20 0.39
ACVR1B P36896 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GAPDH P04406 1/20 0.39
MAP2K4 P45985 1/20 0.39
PDGFRB P09619 1/20 0.39
SNCA P37840 1/20 0.38
NPC1 O15118 5/20 0.38
MAPT P10636 5/20 0.38
KDM4E B2RXH2 4/20 0.38
RAB9A P51151 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
ALDH1A1 P00352 3/20 0.38
LMNA P02545 2/20 0.38
NFKB1 P19838 2/20 0.38
NFKB2 Q00653 2/20 0.38
RELA Q04206 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5930906 0.85 SNCA (0.46) DCUN1D1TGFBR1MAPK14RIPK2ACVR1B
SCHEMBL3242826 0.84 TGFBR1 (0.55) DCUN1D1TGFBR1MAPK14RIPK2ACVR1B
SCHEMBL5138649 0.81 TGFBR1 (0.41) DCUN1D1TGFBR1MAPK14RIPK2ACVR1B
SCHEMBL5138816 0.81 KDM4E (0.43) DCUN1D1TGFBR1MAPK14RIPK2ACVR1B
SCHEMBL5139522 0.81 TGFBR1 (0.48) DCUN1D1TGFBR1MAPK14RIPK2ACVR1B
SCHEMBL5139510 0.81 SNCA (0.40) DCUN1D1TGFBR1MAPK14RIPK2ACVR1B
SCHEMBL5138590 0.79 TGFBR1 (0.39) DCUN1D1TGFBR1MAPK14RIPK2ACVR1B
SCHEMBL5138656 0.79 TGFBR1 (0.41) DCUN1D1TGFBR1MAPK14RIPK2ACVR1B
SCHEMBL5138410 0.79 TGFBR1 (0.39) DCUN1D1TGFBR1MAPK14RIPK2ACVR1B
SCHEMBL5138587 0.79 TGFBR1 (0.39) DCUN1D1TGFBR1MAPK14RIPK2ACVR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1804801-A2 METHODS OF TREATING VASCULAR INJURIES Biogen Idec MA, Inc. (US) 2007-07-11 EP claimed
US-20060264440-A1 Pyrazoles and methods of making and using the same BIOGEN IDEC MA INC. (US) 2006-11-23 US claimed
EP-1596656-A4 PYRAZOLES AND METHODS OF MAKING AND USING THE SAME BIOGEN IDEC INC (US) 2006-10-18 EP claimed
JP-2006517592-A 2006-07-27 JP claimed
WO-2006044509-A2 METHODS OF TREATING VASCULAR INJURIES BIOGEN IDEC MA INC. (US) 2006-04-27 WO claimed
EP-1596656-A2 PYRAZOLES AND METHODS OF MAKING AND USING THE SAME Biogen Idec MA Inc. (US) 2005-11-23 EP claimed
WO-2004072033-A2 PYRAZOLES AND METHODS OF MAKING AND USING THE SAME BIOGEN IDEC MA INC. (US) 2004-08-26 WO claimed
WO-2008013928-A2 TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR BIOGEN IDEC MA INC. (US) 2008-01-31 WO disclosed
EP-1804801-A2 METHODS OF TREATING VASCULAR INJURIES Biogen Idec MA, Inc. (US) 2007-07-11 EP disclosed
US-20060264440-A1 Pyrazoles and methods of making and using the same BIOGEN IDEC MA INC. (US) 2006-11-23 US disclosed
EP-1596656-A4 PYRAZOLES AND METHODS OF MAKING AND USING THE SAME BIOGEN IDEC INC (US) 2006-10-18 EP disclosed
WO-2006044509-A2 METHODS OF TREATING VASCULAR INJURIES BIOGEN IDEC MA INC. (US) 2006-04-27 WO disclosed
EP-1596656-A2 PYRAZOLES AND METHODS OF MAKING AND USING THE SAME Biogen Idec MA Inc. (US) 2005-11-23 EP disclosed
WO-2004072033-A2 PYRAZOLES AND METHODS OF MAKING AND USING THE SAME BIOGEN IDEC MA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264440-A1 Pyrazoles and methods of making and using the same ALK, ACVR1, ALKBH5 DCUN1D1 4271/4885TGFBR1 26/4885MAPK14 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.